Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:42 PM
Ignite Modification Date:
2025-12-24 @ 9:42 PM
NCT ID:
NCT00237432
Eligibility Criteria:
Inclusion Criteria:
* Patients with confirmed HCV infection based on serologic studies and/or plasma HCV titers
* Individuals who have recovered from toxicity of any prior therapy and who have not had IFN-α and/or ribavirin therapy in the last 6 months
* Performance status: Karnofsky 70-100%
* Life expectancy of at least 12 months
* Hematology laboratory results of:
* WBC greater than 3,800/mm3
* Absolute lymphocytes greater than 1,500/mm3
* Platelets greater than 120,000/mm3
* Hb at least 9.5 g/dl
* INR \< 1.5 IU
Exclusion Criteria:
* Patients who are currently on immunotherapy
* Individuals who are currently on antibiotics
* Individuals who have had chemotherapy within the last year for other medical conditions
* Individuals who have had corticosteroid treatment or radiotherapy within the last 4 weeks
* Individuals infected with HIV, syphilis or hepatitis B or with other serious uncontrolled medical illness
* People with currently active second malignancy other than non-melanoma skin cancer
* No history of vasculitis
* No alcohol or drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
* No patients with decompensated cirrhosis
* No NYHA class III/IV status
* No severe debilitating pulmonary disease
* No psychiatric illness or social condition that, in the opinion of the investigator, would interfere with adherence to study requirements
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00237432
Study Brief:
Protocol Section:
NCT00237432